0001193125-26-222890
SEC filingCorbus Pharmaceuticals appointed Brent Pfeiffenberger to its Board of Directors and secured stockholder approval to increase its 2024 Equity Compensation Plan share reserve by 3,000,000 shares to 5,000,000 shares, expanding director capacity and equity incentive flexibility.
The appointment of Dr. Brent Pfeiffenberger adds deep oncology commercialization and biotech leadership to Corbus’s Board at a pivotal clinical stage: CRB-701 data is set for ASCO 2026, FDA alignment on its registrational path has been confirmed, and CRB-913’s CANYON-1 study nears completion. His background — including leading Bristol-Myers Squibb’s multi-billion-dollar U.S. Oncology franchise and steering Neogene’s growth to acquisition by AstraZeneca — directly addresses strategic gaps in scaling late-stage assets. Concurrently, the 3,000,000-share increase to the 2024 Equity Compensation Plan significantly expands the pool available for future director, officer, and employee grants, supporting retention and alignment ahead of anticipated value inflection points. While no specific equity award terms were finalized for Dr. Pfeiffenberger, the Board’s commitment to granting one underscores his expected strategic role. The shareholder vote outcomes reflect broad support across governance items, with notable broker non-votes (4.06M) consistent with typical proxy mechanics but not indicative of dissent on the equity plan amendment, which passed with majority support among voting shares. No financial metrics, guidance, or material agreements beyond the plan amendment and indemnification agreement are disclosed.